KR20140077911A - 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 - Google Patents

암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 Download PDF

Info

Publication number
KR20140077911A
KR20140077911A KR1020147009539A KR20147009539A KR20140077911A KR 20140077911 A KR20140077911 A KR 20140077911A KR 1020147009539 A KR1020147009539 A KR 1020147009539A KR 20147009539 A KR20147009539 A KR 20147009539A KR 20140077911 A KR20140077911 A KR 20140077911A
Authority
KR
South Korea
Prior art keywords
nhc
phenyl
compound
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147009539A
Other languages
English (en)
Korean (ko)
Inventor
아서 데실리스
로드리고 루이즈 소토
개리 토마스 에몬스
조앤 라거
Original Assignee
엑셀리시스, 인코포레이티드
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑셀리시스, 인코포레이티드, 사노피 filed Critical 엑셀리시스, 인코포레이티드
Publication of KR20140077911A publication Critical patent/KR20140077911A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147009539A 2011-09-14 2012-09-14 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 Withdrawn KR20140077911A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161534836P 2011-09-14 2011-09-14
US61/534,836 2011-09-14
US201161543529P 2011-10-05 2011-10-05
US61/543,529 2011-10-05
US201161562670P 2011-11-22 2011-11-22
US61/562,670 2011-11-22
PCT/US2012/055387 WO2013040337A1 (en) 2011-09-14 2012-09-14 Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20140077911A true KR20140077911A (ko) 2014-06-24

Family

ID=46940622

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147009539A Withdrawn KR20140077911A (ko) 2011-09-14 2012-09-14 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제

Country Status (10)

Country Link
EP (1) EP2755654A1 (https=)
KR (1) KR20140077911A (https=)
AU (1) AU2012308414A1 (https=)
BR (1) BR112014005858A2 (https=)
CA (1) CA2848724A1 (https=)
IL (1) IL231448A0 (https=)
IN (1) IN2014CN02671A (https=)
TW (1) TW201325592A (https=)
UY (1) UY34339A (https=)
WO (1) WO2013040337A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113754565B (zh) * 2021-11-09 2022-02-22 南京威凯尔生物医药科技有限公司 一种连续流微反应器中制备沙库巴曲中间体的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2007044481A1 (en) 2005-10-07 2007-04-19 Basf Corporation Clearcoat coating composition
CN101395155A (zh) 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
BRPI0617162B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
BRPI0810208A2 (pt) * 2007-04-11 2014-10-21 Exelixis Inc Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.
WO2010146391A1 (en) * 2009-06-15 2010-12-23 Generics [Uk] Limited Regioselective synthesis of letrozole
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use

Also Published As

Publication number Publication date
IL231448A0 (en) 2014-04-30
WO2013040337A1 (en) 2013-03-21
BR112014005858A2 (pt) 2017-06-13
TW201325592A (zh) 2013-07-01
EP2755654A1 (en) 2014-07-23
CA2848724A1 (en) 2013-03-21
WO2013040337A9 (en) 2014-04-03
UY34339A (es) 2013-04-30
IN2014CN02671A (https=) 2015-07-03
AU2012308414A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
CN107286077B (zh) 一种选择性的c-kit激酶抑制剂
CN103874494A (zh) 使用pi3k/mtor的吡啶并嘧啶酮抑制剂与苯达莫司汀和/或利妥昔单抗治疗恶性血液病的组合疗法
CN103874689B (zh) Akt抑制剂化合物和威罗菲尼的组合及使用方法
KR20230167053A (ko) 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법
CN109982701B (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
JP2021502388A (ja) Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
JP5901634B2 (ja) キナゾリン化合物及びその使用方法
EP4165035A1 (en) Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
CN113149985A (zh) 六氢咪唑并吡啶并嘧啶酮、其类似物和盐、及其治疗用途
KR20230167050A (ko) 암 치료를 위해 prmt5 저해제를 사용하는 병용 요법
JP2021530486A (ja) 選択的エストロゲン受容体分解剤
JP2009539962A (ja) Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
CN111606887B (zh) 一种新型激酶抑制剂
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
CN105050602B (zh) 作为pi3激酶抑制剂的吡啶化合物
CN103635183A (zh) 使用pi3k/mtor的吡啶并嘧啶抑制剂来治疗淋巴瘤的方法
TWI863667B (zh) 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
KR20140077911A (ko) 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제
CN121175049A (zh) 治疗包含非典型egfr突变的癌症的egfr抑制剂
KR101663335B1 (ko) 6-（1-메틸-1ｈ-피라졸-4-일）-2-｛3-［5-（2-모르폴린-4-일-에톡시）-피리미딘-2-일］-벤질｝-2ｈ-피리다진-3-온디히드로겐포스페이트의 신규한 다형체 및 이의 제조 방법
WO2023010102A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
JP2022542697A (ja) 癌治療用ジヌクレオチド化合物及びその医薬用途
WO2013067306A1 (en) Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
WO2026076001A1 (en) Compositions and methods for use in the treatment of cancer and other indications
WO2013056067A1 (en) Compounds for use in the treatment of basal cell carcinoma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140410

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid